Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
|Articles|July 1, 2010
USP's 2010-2015 Council of Experts Chairs
USP's 2010-2015 Council of Experts Chairs
Advertisement
Monographs — Small Molecules 1 Expert Committee
Glenn A. Van Buskirk, PhD
Monographs — Small Molecules 2 Expert Committee
Ernest Parente, PhD
Monographs — Small Molecules 3 Expert Committee
Bernard Olsen, PhD
Monographs — Small Molecules 4 Expert Committee
Michael A. Cutrera, MSc
Monographs — Biologics & Biotechnology 1 Expert Committee
Michael G. Mulkerrin, PhD
Monographs — Biologics & Biotechnology 2 Expert Committee
Jean F. Huxsoll, PhD
Monographs — Excipients Expert Committee
Lawrence H. Block, PhD
Monographs — Dietary Supplements Expert Committee
Dennis K. J. Gorecki, PhD
Monographs — Food Ingredients Expert Committee
Andrew G. Ebert, PhD
General Chapters — Chemical Analysis Expert Committee
Timothy J. Wozniak, PhD
General Chapters — Physical Analysis Expert Committee
Gregory E. Amidon, PhD
General Chapters — Biological Analysis Expert Committee
Wesley E. Workman, PhD
General Chapters — Dosage Forms Expert Committee
James E. DeMuth, PhD
General Chapters — Microbiology Expert Committee
James E. Akers, PhD
General Chapters — Packaging, Storage, and Distribution Expert Committee
Mary G. Foster, PharmD, BFA
Nomenclature, Safety, and Labeling Expert Committee
Thomas P. Reinders, PharmD
Compounding Expert Committee
Gigi S. Davidson, BS, RPh, DICVP
Reference Standards Expert Committee
Matthew W. Borer, PhD
Statistics Expert Committee
Robert Singer, MS
Toxicology Expert Committee
Robert E. Osterberg, PhD
Advertisement
Related to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Advertisement
Advertisement